Endo, Inc. (“Endo” or the “Company”) (OTCQX: NDOI) announces it has entered into a definitive agreement to divest its International Pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma Inc., to Knight Therapeutics Inc. for a total consideration of up to $99 million, consisting of an upfront cash payment of $84 million and up to an additional $15 million in potential future payments contingent upon the achievement of certain milestones. Knight Therapeutics is a specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing and commercializing innovative prescription pharmaceuticals, primarily serving Canada and Latin America.
Read the full article: Endo Announces Divestiture of International Pharmaceuticals Business //
Source: https://www.prnewswire.com/news-releases/endo-announces-divestiture-of-international-pharmaceuticals-business-302397770.html